-
Most Recent
Search Results
240 results for abb
Copper, the AI Gold Rush, and 12 Stocks to Avoid
Is FCX’s pullback a buying opportunity?… Eric Fry’s “builders vs. appliers” framework explained… 12 applier stocks that Jonathan Rose is warning about
3 Stocks to Sell Before May 19
If history is any guide, the market’s first reaction will be dangerously incomplete. Fortunately, many industry insiders are already giving clues about which firms will…
ABB’s Global Expansion Makes It a Solid Value Play
ABB’s focus on globalization and maximizing operations efficiency make it a solid value play.
AbbVie Inc: ABBV Stock Is a Prescription for Profits
Investors and traders should be positioning themselves in AbbVie stock. This trade on ABBV will help you limit earnings volatility while allowing you to enjoy…
ABBV Stock Slips as AbbVie Faces Opioid Lawsuits
AbbVie’s quarterly results were roughly in line with Wall Street’s expectations, but ABBV stock still slipped in early trading.
AbbVie Inc Dividend at Risk Amid Patent Protection Problems
ABBV remains a strong holding for dividend growth, but AbbVie is about to lose patent protection on Humira, which accounts for two-thirds of its revenue.
$192 Price Target Makes AbbVie Stock a Notable Healthcare Pick
ABBV stock could have substantial room to run as a big-bank analyst assigns a high rating to relentlessly innovative AbbVie.
What Are AbbVie Shareholders Getting for Their $21 Billion? (ABBV, PCYC, JNJ)
AbbVie (ABBV) beat Johnson & Johnson (JNJ) to the punch with the deal to acquire Pharmacyclics (PCYC), but was it worth the hefty price tag?
Consistent Clinical Results Indicate Upside for AbbVie Stock
ABBV stock can move higher as it trades at a very reasonable valuation. Meanwhile, AbbVie’s financials and dividend payments sweeten the deal.
Strong Buy for AbbVie (ABBV) This Week
At $114.93, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares.
Strong Buy for AbbVie (ABBV) This Week
At $118.94, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares.
Best Stocks for 2022: Why AbbVie Looks Like High Dividend Growth Stock
A solid year and an excellent third-quarter report from AbbVie has ABBV stock looking like it is one of the best stocks to buy for…
ABBV Stock: The FDA Blow That Just Sent AbbVie Tumbling on Wednesday
Here’s the big FDA-related news today that’s sparking a sharp selloff of pharmaceutical giant AbbVie and ABBV stock.
Why AbbVie Inc Was a Named Top Dividend Stock (ABBV)
AbbVie Inc has been named to the Dividend Channel’s SAFE dividend list based upon these key metrics
AbbVie Stock: 3 Pros and 3 Cons to Consider Before Investing in ABBV
AbbVie has significant challenges, but they’re also not unique ones. Sizing up the outlook leads to a slightly bullish stance on ABBV stock.
The Humira Overhang Can’t Cast a Shadow on AbbVie Stock Forever
If you’re thinking about stepping into AbbVie stock here, you’re not crazy. The challenge is simply getting everyone else to believe in ABBV stock.
Why AbbVie Inc (ABBV) Stock Is Still a Long-Term Winner
The market has been hot and cold on biotechs, but AbbVie stock is a great long-term winner. Here’s what you need to know about ABBV.
AI’s $700 Billion Question
Alphabet says AI demand is outrunning supply … AWS logs its fastest growth in four years … Meta beats but pulls back 10% … and…
AbbVie Earnings: ABBV Stock Pops on Q2 Beat
AbbVie earnings for the second quarter of 2019 have ABBV stock up on Friday thanks to it beating EPS and revenue estimates.
ABBV: AbbVie Beats Street on Soaring Humira Sales
Pharmaceutical-maker AbbVie posted first-quarter sales that beat estimates on surging sales of its Humira drug, sending ABBV stock higher.
AbbVie Earnings: ABBV Stock Falters on Q4 Miss
AbbVie earnings for the fourth quarter of 2018 saw ABBV stock falling today after reporting an earnings per share and revenue miss.
AbbVie (ABBV) a Strong Buy at $117.98
At $117.98, AbbVie (ABBV) a Strong Buy based on the latest SEC filings, and comparative pricing of its shares.
AbbVie Inc (ABBV) Has More Blockbusters on the Horizon
AbbVie (ABBV) isn’t just resting on the success of Humira; this major pharmaceutical firm is building for a long, strong future.
AbbVie Earnings: ABBV Stock Drops 2% Despite Q2 Beats
AbbVie earnings on Friday have ABBV stock slighty lower despite the company beating EPS and revenue estimates from Wall Street.
2 – 10 of 240 results
